Gastrointestinal Adverse Events Gastrointestinal (GI) adverse events are the hallmark safety finding with all GLP-1 receptor agonists, reflecting the physiological effects of GLP-1 signaling on gastric motility, gastric emptying, and central appetite regulation
Studies published within the last 10 years to reflect current clinical practices and drug development
Semaglutide, the active ingredient in Ozempic, is also found in other weight loss treatments like Wegovy, which is specifically approved for weight loss
What makes tirzepatide even more helpful is it also imitates a second hormone, called GIP, which along with reducing appetite may also improve how the body breaks down sugar and fat, helping to amplify the weight loss effects
It is speculated that the hypoglycemic effect may be related to flavonoids in the extract inhibiting glucose absorption and promoting insulin secretion
Success with semaglutide goes beyond taking the right dose